

PROACTIVE MONITORING OF INFLIXIMAB IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE OVER A 4-YEAR PERIOD

S. Clemente Bautista¹, O. Segarra Cantón², S. García García S¹, M. Álvarez Beltrán², M. Larrosa García¹, MJ Cabañas Poy¹, MT. Sanz Martínez, M. Freixas Bermejo², A. Mariscal Puig¹, MQ. Gorgas Torner¹, M. Miarons Font^{1,4}

1. Department of Pharmacy. 2. Paediatric Gastroenterology Unit. 3. Clinics Laboratories Service. Vall d'Hebron University Hospital, Barcelona, Spain. 4. Department of Pharmacy. Consorci Hospitalari, Vic. Barcelona, Spain

BACKGROUND AND IMPORTANCE

Preliminary data suggest that proactive therapeutic drug monitoring (TDM) guides dose adjustment to achieve appropriate trough concentrations (Cmin), reducing the risk of treatment failure (TF) and improving safety.



AIM AND OBJECTIVE

To analyse the experience of a multidisciplinary

proactive TDM programme for infliximab (IFX) in children with inflammatory bowel disease (IBD) (Crohn's disease (CD) and Ulcerative Colitis (UC))

MATERIALS AND METHODS

Prospective single-centre study Third-level hospital

VARIABLES:



→ Clinical

†,†,†

- → Analytical
- → TDM
- ✓ **Efficacy :** TF, IBD-related surgery, and hospitalisation.
- ✓ Adverse reactions (AR).



Children with IBD treated with intravenous IFX

September 2019 - September 2023

- IFX Cmin and anti-infliximab antibodies (ATI) were determined by **ELISA** or **chemiluminescence**.
- Dose individualisation

 population pharmacokinetic

 model of Fasanmade et al (2011). \rightarrow NONMEM v7.4.3.
- **IFX Cmin** was monitored at induction and every six months
- Target Cmin (μg/ml): 1-3 week(w): >25 ; 6-7w: >15; maintenance: 5-8.

RESULTS

N= 33 patients \rightarrow 21 male; 18 CD/15 UC. Age diagnosis: median (IQR): 11.58 (6.87-14.04) years old

- 794 administrations; 290 IFX Cmin
- **Dosage** (mg/kg): mean(SD): **8.66 (±2.22)**
- **IFX Cmin** (μg/ml) (mean, SD): Induction

1-3 w: 25.71 (±19.50)

6-7 w: 13.63 (±7.73)

14 w: : 14.60 (±8.01)

TF; n (%)	6 (18.18)
primary (n)	2
secondary (n)	4
Causes (%):	
 pharmacodynamic failure 	66.37
 severe IR related ATI 	16.67

severe ik related ATI


- 16.67 other ARs 6 (18) Hospitalizations; n (%) Causes (%):
- **IBD** complications
- AR

Emergency visits; n (%)	4 (12.12)
Causes (%):	

62.50

37.50

Adverse reactions IR Infections Paradoxical psoriasis




48.72% of the **ARs** were classified as **severe** (prevented the patients performing normal daily activities)


Posologies adjustments:



10.47 (±8.47)



*IR: infusion reaction



CONCLUSION AND RELEVANCE



Multidisciplinary proactive TDM programme has allowed to successfully adjust IFX doses in paediatric patients, obtaining promising clinical results similar to those reported in adults (Papamichael et al. 2017) and Sánchez-Hernández et al. 2020).

